Connect with us

EU

#JunckerPlan supports chronic disease prevention in #Finland

SHARE:

Published

7 years ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The Investment Plan for Europe, or Juncker Plan, is backing a €20 million European Investment Bank (EIB) loan to Finnish company Nightingale Health. The company will use the financing to further develop its blood analysis technology, which facilitates the detection and prevention of chronic diseases.

Jobs, Growth, Investment and Competitiveness Vice President Jyrki Katainen, who attended the signature event in Helsinki, said: "Europe invests heavily in education and science as we believe that putting a strategic effort into these areas can reap huge benefits. This commitment has resulted in Europe's position today as a world leader in cutting edge medical research. We are delighted that the Investment Plan for Europe is fostering the development of Nightingale's technology which has the potential to add significant value to European healthcare."

Nightingale's innovative blood analysis technology can detect early signs of chronic diseases, improving for example the assessment of a person's future risk of developing heart disease or type 2 diabetes. A press release is available here. As of December 2018, the European Fund for Strategic Investments (EFSI), at the heart of the Juncker Plan, had already mobilized €371.2 billion of additional investments, including €7.8bn in Finland.

Share this article:

Share this:
Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending